The present invention relates to (2R, 5S, 13aR) -8-hydroxy-7,9-dioxo-N- (2,4,6-trifluorobenzyl) -2,3,4,5,7,9,13, 13a-Octahydro-2,5-methanopyrido [1 ′, 2 ′: 4,5] Pyrazino [2,1-b] [1,3] oxazepine-10-carboxamide crystal forms and co-crystals, pharmaceutical preparations, and Relates to the therapeutic use of. The present invention also provides sodium (2R, 5S, 13aR) -7,9-dioxo-10-((2,4,6-trifluorobenzyl) carbamoyl) -2,3,4,5,7,9,13. , 13a-octahydro-2,5-methanopyrido [1 ′, 2 ′: 4,5] pyrazino [2,1-b] [1,3] oxazepine-8-olate Form I relates to a novel crystal form. [Selection] Figure 1本発明は、(2R,5S,13aR)-8-ヒドロキシ-7,9-ジオキソ-N-(2,4,6-トリフルオロベンジル)-2,3,4,5,7,9,13,13a-オクタヒドロ-2,5-メタノピリド[1’,2’:4,5]ピラジノ[2,1-b][1,3]オキサゼピン-10-カルボキサミドの結晶形および共結晶、医薬製剤、ならびにそれらの治療的使用に関する。本発明はまた、ナトリウム(2R,5S,13aR)-7,9-ジオキソ-10-((2,4,6-トリフルオロベンジル)カルバモイル)-2,3,4,5,7,9,13,13a-オクタヒドロ-2,5-メタノピリド[1’,2’:4,5]ピラジノ[2,1-b][1,3]オキサゼピン-8-オレートI型の新規な結晶形に関する。【選択図】図1